Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have demonstrated to be highly efficient in treating solid tumors; however, many patients have limited benefits in terms of response and survival. This rapidly led to the investigation of combination therapies to enhance response rates. Moreover, predictive biomarkers were assessed to better select patients. Although PD-L1 expression remains the only validated marker in clinics, molecular profiling has brought valuable information, showing that the tumor mutation load and microsatellite instability (MSI) status were associated to higher response rates in nearly all cancer types. Moreover, in lung cancer, EGFR and MET mutations, oncogene fusions or STK11 inactivating mutations were associated with low response rates. Cancer progression towards invasive ph

SUBMITTER: Perrier A 

PROVIDER: S-EPMC7407667 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature